Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis

Rebeca Sanz-Pamplona 1,2,3, Marilena Melas 4, Asaf Maoz 5, Stephanie L Schmit 6, Hedy Rennert 7, Flavio Lejbkowicz 7, Joel K Greenson 8, Xavier Sanjuan 9, Maria Lopez-Zambrano 9, M Henar Alonso 1,2,3 10, Chenxu Qu 11, Kevin J McDonnell 11, Gregory E Idos 11, Marissa Vignali 12, Ryan Emerson 12, Paul Fields 12, Elisabet Guinó 1,2,3, Cristina Santos 1,2,13, Ramon Salazar 1,2,13, Harlan S Robins 12,14, Gad Rennert 7, Stephen B Gruber 11, Victor Moreno 1,2,3,10; 1 Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain. 2 ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 3 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Spain. 4 Nationwide Children's Hospital, Columbus, Ohio, United States of America. 5 Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America. 6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America. 7 Carmel Medical Center, and Technion, Haifa, Israel. 8 University of Michigan Medical School, Ann Arbor, Michigan, United States of America. 9 University Hospital Bellvitge (HUB-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. 10 Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain. 11 City of Hope National Medical Center, Duarte, California, United States of America. 12 Adaptive Biotechnologies, Seattle, Washington, United States of America. 13 Consortium for Biomedical Research in Oncology (CIBERONC), Spain. 14 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.